OnKure (OKUR): Market Cap to Revenue Ratio

Corporate company logo of OnKure (OKUR)

High patent barriers and stringent FDA oversight limit entry into the oncology inhibitor sector, while the GURU.Markets portal displays revenue multiple dynamics, where captures the current state of the parameter. Investors value the scientific authority of OnKure Therapeutics Inc (OKUR) in the development of targeted PI3K drugs. Supply chain reliability is ensured through the flawless express delivery of chilled research samples.

Market Cap to Revenue: onkuretherapeutics.com (OKUR) for 07/04/2022 - 11/18/2026

Analytical breakdowns for OnKure Therapeutics Inc (OKUR)

- current quotes and average value forecast:
Summary company analytics:onkuretherapeutics.com, OKUR
Finished products of OnKure

The P/S multiple reflects the market value of the business relative to its total revenue, allowing for an assessment of asset monetization efficiency. Comparing current values with the median P/S helps investors determine the degree of company overvaluation relative to historical norms. For OnKure Therapeutics Inc (OKUR), this indicator is critical as it reflects market expectations for the future commercialization of drugs. A high ratio here is justified by the potential for patent scalability, which could multiply the returns on current R&D expenditures.

Who OnKure Therapeutics Inc competes with

ONC - Price to Sales|P/S Multiple HALO (Halozyme Therapeutics, Inc.)|Revolution Medicines (RVMD) - Price to Sales|ascentage.com - P/S Multiple|Market Capitalization-to-Revenue Ratio CGON (cgoncology.com)|URGN: P/S Multiple|Bicara Therapeutics Inc (BCAX) - P/S Multiple|Price-to-Revenue Ratio personalis.com|Market Cap to Revenue Erasca Corp (ERAS)|Market Cap to Revenue DCTH (Delcath)|Price-to-Revenue Coefficient Y-mAbs Therapeutics, Inc.|P/S Multiple AURA (Aura Biosciences Inc)|Market Capitalization-to-Revenue Ratio CADL|ARAY: Market Cap to Revenue|Price-to-Revenue Coefficient sellaslifesciences.com SLS|ACTU (Actuate Therapeutics, Inc) - Market Cap to Revenue|Market Cap to Revenue Ratio CTOR|Price-to-Revenue Ratio TuHURA Biosciences Inc.|TARA: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Fate Therapeutics (FATE)|Price-to-Revenue Coefficient Aadi Bioscience|Price-to-Revenue Ratio TScan Therapeutics Inc TCRX|CSBR: Market Cap to Revenue Ratio|XBIT: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio CVM (cel-sci.com)|OSTX: P/S Multiple|Price to Sales Radiopharm Theranostics Ltd (RADX)|ARTV (Artiva) - P/S Multiple|Market Cap to Revenue Ratio ANL (Adlai Nortye)|Price-to-Revenue Ratio Veru Pharma (VERU)|P/S Multiple Tempest Tx (TPST)|Price-to-Revenue Ratio xiliotx.com XLO|Enochian BioSciences - Price-to-Revenue Ratio|Mural Oncology - P/S Multiple|KAPA - P/S Multiple|GDTC: P/S Multiple|Price to Sales Curis Corp (CRIS)|APLM (apollomicsinc.com) - P/S Multiple|Market Cap to Revenue Tharimmune Corp (THAR)|P/S Multiple ADVB|GNPX - Price to Sales|Price-to-Revenue Ratio calidibio.com CLDI|SBFM - Market Cap to Revenue|XBIO - Price-to-Revenue Ratio|SLRX: Price-to-Revenue Ratio|Purple Biotech (PPBT) - Price-to-Revenue Ratio|AON - Market Capitalization-to-Revenue Ratio|Market Cap to Revenue BGNE|P/S Multiple Checkpoint Therapeutics Inc.|P/S Multiple ELEV|Market Cap to Revenue iCAD ICAD|P/S Multiple IKNA (Ikena Oncology, Inc.)|Market Capitalization-to-Revenue Ratio NTBL|Viracta Therapeutics, Inc. - P/S Multiple|Market Capitalization-to-Revenue Ratio MOR (MorphoSys Inc)|NAYA (NAYA Biosciences Inc) - Market Cap to Revenue|Market Cap to Revenue Ascentage Pharma Group Ltd